A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients (FRESCO)

  • Interventional
  • Recruiting
  • NCT02314819
Eligibility Details Visit Clinicaltrials.gov

A Randomized, Double-blind and Placebo-controlled Phase III Trial Comparing Fruquintinib Efficacy and Safety vs Best Support Care (BSC) in Advanced Colorectal Cancer Patients Who Have Failed at Least Second Lines of Chemotherapies

Fruquintinib administered at 5mg once daily(QD) in 4 weeks treatment cycle (three weeks on and one week off) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with metastatic colorectal cancer (CRC) in phase Ib and phase 2 study. This study is aimed to evaluate the efficacy and safety of Fruquintinib in the treatment of patients with metastatic CRC who have progressed after second line or above standard chemotherapy

This is a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial to compare the efficacy and safety of Fruquintinib plus BSC versus placebo plus BSC in patients with metastatic colorectal cancer who have progressed after second-line or above standard chemotherapy. After checking eligibility criteria, subjects will be randomized into Fruquintinib plus BSC group (treatment group) or placebo plus BSC group (control group) in a ration of 2:1. Primary Efficacy Endpoint: Overall Survival (OS). Secondary Efficacy Endpoints: Progression free survival (PFS) (According to RECIST Version 1.1), Objective Response Rate (ORR), Disease Control Rate (DCR), . Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 4.0.


Age Group
18 Years to 75 Years

Accepting Healthy Volunteers?

Inclusion Criteria:

         - ≥ 18 and ≤ 75 years of age , with ≥ 40Kg

         - Histological or cytological confirmed colorectal cancer

         - ECOG performance status of 0-1

         - Standard regimen failed or no standard regimen available

         - Adequate hepatic, renal, heart, and hematologic functions

         - At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)

         - Signed and dated informed consent

         - Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure

        Exclusion Criteria:

         - - Pregnant or lactating women

         - Any factors that influence the usage of oral administration

         - Evidence of CNS metastasis

         - Intercurrence with one of the following: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure

         - Abuse of alcohol or drugs

         - Less than 4 weeks from the last clinical trial - Previous treatment with VEGFR inhibition

         - Disability of serious uncontrolled intercurrence infection

         - Proteinuria ≥ 2+ (1.0g/24hr)

         - Have evidence or a history of bleeding tendency within two months of the enrollment, regardless of seriousness

         - Within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.

         - Within 6 months before the first treatment occurs acute myocardial infarction, acute coronary syndrome or CABG

         - Bone fracture or wounds that was not cured for a long time

         - Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy

At a Glance

National Government IDNCT02314819


Lead SponsorHutchison Medipharma Limited

Lead PhysicianArdaman Shergill


18 Years to 75 Years